Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

(2017) David A Margolis et al.   LANCET

Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial

(2017) Martin Markowitz et al.   Lancet HIV

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

(2015) David A Margolis et al.   LANCET INFECTIOUS DISEASES

Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women

(2015) Jeanne M. Marrazzo et al.   NEW ENGLAND JOURNAL OF MEDICINE

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection

(2015) Jean-Michel Molina et al.   NEW ENGLAND JOURNAL OF MEDICINE

The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge

(2015) J. Radzio et al.   Science Translational Medicine

Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment fromin vitrostudies and a clinical investigation with midazolam

(2015) Melinda J. Reese et al.   XENOBIOTICA

Formulation and pharmacology of long-acting cabotegravir

(2015) Christine Trezza et al.   Current Opinion in HIV and AIDS

Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus

(2014) C. D. Andrews et al.   SCIENCE

Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor

(2013) W. Spreen et al.   HIV CLINICAL TRIALS

Dolutegravir: A New Integrase Strand Transfer Inhibitor for the Treatment of HIV

(2013) Bhavik M. Shah et al.   PHARMACOTHERAPY

The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated Adults

(2012) Mark R. Underwood et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

(2012) Joseph J. Eron et al.   JOURNAL OF INFECTIOUS DISEASES

Global epidemiology of HIV infection in men who have sex with men

(2012) Chris Beyrer et al.   LANCET

Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women

(2012) Jared M. Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preexposure Prophylaxis for HIV Infection among African Women

(2012) Lut Van Damme et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

(2011) Sherene Min et al.   AIDS

State of the art of nanocrystals – Special features, production, nanotoxicology aspects and intracellular delivery

(2011) Rainer H. Müller et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men

(2010) Robert M. Grant et al.   NEW ENGLAND JOURNAL OF MEDICINE

HIV-1 IN Inhibitors: 2010 Update and Perspectives

(2009) Christophe Marchand et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY